VivoSeq
Other

GATA2

8

Pipeline Programs↗

2

Active Trials↗

5

Companies Involved↗

GATA2 is an early-stage landscape with 8 programs across 5 companies. The most active players are Sanofi, Akero Therapeutics, Roche.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Akero Therapeutics logo

Akero Therapeutics

1 program

Phase 2Roche logo

Roche

1 program

Phase 2V

Veloxis Pharmaceuticals

1 program

Phase 2J

Jasper Therapeutics, Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

78%

Small molecule

7 of 9 classified programs — the dominant modality here.

22%ALL OTHERSMonoclonal antibody111%Cell therapy111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Active, not recruiting1 · 50%

Clinical Trials

Trial Activity

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT01861106·144 enrolled
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT05907746·13 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)